skip to main content

ANCA Vasculitis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardVasculitisANCA VasculitisSCE Rheumatology

A patient with GPA reaches remission after rituximab-based induction. Which maintenance regimen best reflects the 2025 BSR recommendation when there is no contraindication?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Use rituximab 500–1000 mg every 4–6 months for an individualised 24–48-month course

Explanation lettering: E = shown as C · C = shown as D · D = shown as E

B is correct. BSR prefers rituximab maintenance after rituximab- or cyclophosphamide-based induction, using 500–1000 mg every 4–6 months; duration is usually individualised within a 24–48-month framework. A reverses preference. C exposes the patient to cumulative cyclophosphamide toxicity. D abandons scheduled relapse prevention. E reserves a less effective option for intolerance or contraindication to preferred agents.

Reference: BSR 2025 management recommendations for ANCA-associated vasculitis: https://academic.oup.com/rheumatology/article/64/8/4470/8160140